- Report
- March 2025
- 50 Pages
South Korea
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
India
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Australia
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Japan
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
China
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Spain
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Italy
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
United Kingdom
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Germany
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
France
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Mexico
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Canada
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
United States
From €532EUR$600USD£462GBP
- Report
- August 2023
- 1300 Pages
Global
From €7894EUR$8,900USD£6,847GBP
- Report
- August 2023
- 300 Pages
Africa, Middle East
From €4346EUR$4,900USD£3,770GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4346EUR$4,900USD£3,770GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4346EUR$4,900USD£3,770GBP
- Report
- August 2023
- 300 Pages
Europe
From €4346EUR$4,900USD£3,770GBP
- Report
- August 2023
- 51 Pages
South Korea
From €532EUR$600USD£462GBP
- Report
- August 2023
- 51 Pages
India
From €532EUR$600USD£462GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more